Oculis Holding AG

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
12.85 ^USD	-1.68%		+6.91%	+14.43%

Apr. 24	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT
Apr. 24	Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	CI

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

November 14, 2023

On November 15, 2023, Oculis Holding AG. closed the transaction.

Latest news about Oculis Holding AG

H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	Apr. 24	MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index	Apr. 23	CI
Oculis Completes $59 Million Direct Offering of Shares	Apr. 22	MT
Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development	Apr. 10	CI
Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	Apr. 08	CI
Oculis Holding Files $300 Million Mixed-Securities Shelf Registration	Apr. 01	MT
Baird Adjusts Price Target on Oculis to $35 From $64, Maintains Outperform Rating	Mar. 19	MT
Oculis Narrows Q4 Loss, Improves Cash Position -- Shares Fall	Mar. 18	MT
Oculis Holding AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Oculis Holding AG Announces Executive Appointments	Feb. 28	CI
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery	Dec. 20	CI
Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema	Dec. 18	CI
Oculis Evaluating First Patient in Phase 2b Trial	Dec. 07	MT
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease	Dec. 07	CI
Chardan Initiates Oculis Holding With Buy Rating, Price Target is $30	Dec. 05	MT
Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors	Nov. 14	CI
Oculis Says Phase 3 Stage 1 Trial of Diabetic Macular Edema Drug Candidate Met Primary, Secondary Endpoints	23-10-10	MT
Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress	23-10-10	CI
Stifel Initiates Oculis With Buy Rating, Price Target is $35	23-10-05	MT
Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema	23-10-05	CI
Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer	23-09-11	CI
Wedbush Adjusts Oculis Price Target to $29 From $31, Maintains Outperform Rating	23-08-30	MT
BofA Securities Adjusts Oculis Holding's Price Target to $24 From $23, Keeps Buy Rating	23-08-30	MT
Certain Ordinary Shares of Oculis Holding AG are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI
Certain Warrants of Oculis Holding AG are subject to a Lock-Up Agreement Ending on 30-AUG-2023.	23-08-29	CI

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Retina World Congress

More about the company

Income Statement Evolution

More financial data

Ratings for Oculis Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.58 CHF

Average target price

25.49 CHF

Spread / Average Target

+120.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OCULIS HOLDING AG	+14.43%	533M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
BIO-TECHNE CORPORATION	+0.17%	12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research